New Triple-Drug attack on tough leukemia enters human testing

NCT ID NCT07439211

Not yet recruiting Disease control Sponsor: Jacqueline Garcia, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding a new drug called eganelisib to two standard AML medications (venetoclax and azacitidine) is safe for people with acute myeloid leukemia that has come back or not responded to treatment. About 48 adults will take part to find the best dose and check for side effects. The goal is to control the disease, not to cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia myeloid leukemia refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA LEUKEMIA LEUKEMIA, MYELOID REFRACTORY LEUKEMIA

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.